The Power List 2020 – Advanced Medicine
Chief Executive Officer at Caribou Biosciences
Haurwitz has a research background in CRISPR-Cas biology and holds several patents covering CRISPR-derived technologies. She co-founded Caribou in 2012 and Intellia Therapeutics in 2014, both of which are developing genome editing therapies. Late in 2019, Caribou published a paper showing that their type I CRISPR-Cas platform, FokI-Cascade, can be used to perform genome editing with high precision.